Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study
Neurological Sciences · 2025
DOI: 10.1007/s10072-024-07920-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2025. Verfasst von Aigli G Vakrakou und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND/AIMS: The goal of this study was to assess the clinical profile of myasthenia gravis (MG) in patients diagnosed above 65-years of age (VLOMG) and identify clinical/serological parameters associated with their MG status and prognosis. METHODS: This was a retrospective assessment of consecutive patients with VLOMG (n = 70) Demographics, clinical characteristics, medical comorbidities, the Myasthenia Gravis Foundation of America (MGFA) severity scale scores, and MGFA Post-Intervention Status (MGFA-PIS) were collected. RESULTS: The research population was diagnosed with MG at an average age of 73.16 ± 6.33 years, a male/female ratio of 2.3/1 and a mean follow-up time of 53.09 ± 46.37 months. The titer of acetylcholine receptor antibodies (AChR Abs) was positive at 95.71% of patients. The predominant distribution of myasthenic weakness was oculobulbar (63.79%). At the last follow-up, 75.71% of patients reached Pharmacological-Remission (PR) or Minimal-Manifestations (MM), 17% manifested improvement and 7.14% were clinically unchanged, worse or dead, according to MGFA-PIS. Most patients responded to low doses of steroids. Males and patients with generalized muscle involvement upon disease-onset were more likely to reach PR or MM than females or ocular presentation (OR = 3.84 and O.18, respectively). Six patients (8.57%) were treated with at least one cycle of rituximab due to disease severity. Five (83%) reached PR or MM and one improved (mean follow up time: 7.5 months). INTERPRETATION: We found that patients with VLOMG are usually males, with oculobulbar muscle involvement and positive titer of AChR Abs. The majority had a favorable prognosis and an adequate response to low doses of prednisolone and long-term immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
- Department of Statistics and Insurance Science, School of Economic Sciences, University of Western Macedonia, Kozani, Greece.
- 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece. vzouvelu@med.uoa.gr.
Zitieren
APA
Vakrakou, A. G., Strataki, E., Lymperopoulos, L., Panaretos, D., & Zouvelou, V. (2025). Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study. Neurological Sciences. https://doi.org/10.1007/s10072-024-07920-y
Vancouver
Vakrakou AG, Strataki E, Lymperopoulos L, Panaretos D, Zouvelou V. Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study. Neurological Sciences. 2025. doi:10.1007/s10072-024-07920-y
BibTeX
@article{Vakrakou2025,
author = {Vakrakou, Aigli G and Strataki, Eleni and Lymperopoulos, Loukas and Panaretos, Dimitrios and Zouvelou, Vasiliki},
title = {Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-024-07920-y}
}
EUVIMED